| ||
| Fast Track for Cancer Drugs: Shut It Down or Speed It Up? Medscape "The recent decision by the FDA to remove the breast cancer indication from the label of bevacizumab when clinical trials following the drug's accelerated approval in 2008 did not confirm any survival advantage in this population is an excellent ... See all stories on this topic » | ||
| Groups welcome launch of £200m year Cancer Drugs Fund Pharma Times GSK said it is hoping patients will be able to continue accessing its oncology drugs Tyverb (lapatinib) and Arzerra (ofatumumab) through the CDF, after the Institute rejected the former for breast cancer and the latter for chronic lymphocytic leukaemia ... See all stories on this topic » | ||
| ||
| Belfast team in cancer drug breakthrough Irish Health "We have been able to develop small peptide-based drugs that could be delivered to prevent tumour growth by cutting off their blood supply. This is highly effective in models of prostate and breast cancer. However, this also has the potential for the ... See all stories on this topic » | ||
| Karmanos Scientists Explore Role of Tumor Suppressor Gene in Inhibiting ... PR Newswire (press release) Researchers have studied the role of maspin in breast, lung and prostate cancer and acknowledge that maspin protein is present in the thyroid, pancreas, ovaries and colon. Karmanos doctors are also currently involved in Phase II clinical trials ... See all stories on this topic » | ||
| ARIAD Presents New Preclinical Data on Ponatinib in Solid Tumors ... EON: Enhanced Online News (press release) In a panel of 14 cell lines representing multiple different tumor types including endometrial, bladder, gastric, breast, lung and colon cancer, ponatinib potently and selectively inhibited FGFR-mediated signaling and cell growth. ... See all stories on this topic » |
| ||
| Researchers Turn to Sequencing to Study Genetic Underpinnings of ... Aside from these PGRN projects, a team from Washington University is using sequencing to study drug response in a clinical trial of hormone therapy among breast cancer patients (IS 8/10/2010), researchers from the HudsonAlpha ... - http://www.genomeweb.com/newsletter/10910 | ||
| Futurity.org – Heart drug worthy as prostate therapy By Dennis O'Shea-JHU Serious side effects include male breast enlargement and heart rhythm irregularities, The drug also commonly causes nausea, vomiting, and headache. Derived from leaves of foxglove, a type of flowering plant, digoxin has been ... Disulfiram, used to treat chronic alcoholism, was the top hit on the list of potential anti-prostate cancer drugs, but because it is rarely used among the general population, it could not be evaluated effectively in the epidemiologic study. ... Futurity.org - http://www.futurity.org/ |
| ||
| New Research Gives Insights Into Breast Cancer Drug Resistance They found that breast cancer cells protect themselves against two anti-estrogen drugs (Tamoxifen and Faslodex) by hijacking and switching on a biological ... www.elements4health.com/new-research-gives-insights-into-br... |
This once a day Google Alert is brought to you by Google.
Remove this alert.
Create another alert.
Manage your alerts.
No comments:
Post a Comment